Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold

Maximilian Koch, Johannes S de Jong, Jürgen Glatz, Panagiotis Symvoulidis, Laetitia E Lamberts, Arthur L.L. Adams, Mariëtte E G Kranendonk, Anton G T Terwisscha van Scheltinga, Michaela Aichler, Liesbeth Jansen, Jakob de Vries, Marjolijn N Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D Linssen, Esther de Boer, Bert van der Vegt, Wouter B Nagengast, Sjoerd G. Elias, Sabrina OliveiraArjen J. Witkamp, Willem P.Th M. Mali, Elsken Van der Wall, Beatriz P Garcia-Allende, Paul J. van Diest, Elisabeth G E de Vries, Axel Walch, Gooitzen M van Dam, Vasilis Ntziachristos

Research output: Chapter in Book/Report/Conference proceedingConference contributionAcademicpeer-review

Abstract

In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

Original languageEnglish
Title of host publicationEuropean Conference on Biomedical Optics, ECBO 2017
PublisherOSA - The Optical Society
VolumePart F61-ECBO 2017
ISBN (Electronic)9781557528209
ISBN (Print)9781510612808
DOIs
Publication statusPublished - 2017
EventEuropean Conference on Biomedical Optics, ECBO 2017 - Munich, Germany
Duration: 25 Jun 201729 Jun 2017

Conference

ConferenceEuropean Conference on Biomedical Optics, ECBO 2017
Country/TerritoryGermany
CityMunich
Period25/06/1729/06/17

Keywords

  • Clinical applications
  • Imaging systems
  • Medical and biological imaging

Fingerprint

Dive into the research topics of 'Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold'. Together they form a unique fingerprint.

Cite this